EUCTR2010-021003-24-BE进行中（未招募）1 期
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure - ATOMIC- AHFAcute Treatment with Omecamtiv Mecarbil to increase Contractility - ATOMIC- AHF Acute Treatment with Omecamtiv Mecarbil to increase Contractility
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Amgen Inc
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Subject or subject’s legally acceptable representative has provided informed consent.
- •- Male or female = 18 years and = 85 years of age at the time of randomization.
- •- Current hospitalization for a primary reason of worsening heart failure (determined by the investigator) and requiring IV therapy for heart failure.
- •- History of chronic heart failure (defined as requiring treatment for heart failure for a minimum of 30 days before hospitalization).
- •- History of left ventricular ejection fraction (LVEF) = 40% (echocardiogram, radionuclide ventriculography, cardiac magnetic resonance imaging, or contrast ventriculography) and without an intervening value of > 40%.
- •- Dyspnea due to heart failure, at rest or with minimal exertion, within 24 hours after their initial IV furosemide (or alternative IV loop diuretic) dose and at least 2 hours after having received a total of = 40 mg IV furosemide (or equivalent dose of an alternative IV loop diuretic).
- •- Brain-type natriuretic peptide (BNP) = 400 pg/mL or NT-proBNP = 1600 pg/mL during screening (BNP = 600 pg/mL or NT-proBNP = 2400 pg/mL if the subject has atrial fibrillation at presentation).
- •- Female subjects, if not postmenopausal or sterilized, must have a negative pregnancy test, must not be breastfeeding and must agree to abstain from sexual intercourse or use highly effective methods of birth control during treatment and for 5 days following the last dose of investigational product. Highly effective methods of birth control include: sterilization, birth control pills, Depo-Provera? injections, or contraceptive implants. Postmenopausal female is defined as 12 continuous months of spontaneous amenorrhea.
- •- Male subjects with a partner of childbearing potential must agree to inform their partner of their participation in this clinical study and, during treatment and for 5 days after the last dose of investigational product, to abstain from sexual intercourse or use highly effective methods of birth control, such as: vasectomy or a condom in combination with hormonal birth control or barrier methods used by the woman. For male subjects with pregnant partners, sexual abstinence or a condom must be used for 5 days after the last dose.
- •- If participating in the PK/PD substudy, subject must currently be in sinus rhythm.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 210
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 390
排除标准
- •Disease-specific
- •- Receiving IV vasopressor (excluding dopamine = 5 µg/kg/min), inotropic or mechanical (eg, intra-aortic balloon pump counterpulsation) support between admission to the hospital and randomization.
- •- Subject has a pulmonary artery catheter.
- •- Subject requires endotracheal mechanical ventilation.
- •- Subject has acute coronary syndrome.
- •- Within 30 days prior to enrollment: cardiac resynchronization therapy (CRT) or implantable cardioverter defibrillator (ICD) implantation, hospitalization for acute coronary syndrome, coronary revascularization, transient ischemic attack or stroke, sustained ventricular arrhythmia, or major surgery.
- •- Likely to receive within 30 days after randomization, in the opinion of the investigator, planned revascularization, implantation of ICD or CRT, ventricular assist device, continuous inotropic therapy, intermittent out-patient inotropic therapy, hospice care, or cardiac transplant.
- •- Severe aortic or mitral stenosis or heart failure primarily due to valvular heart disease.
- •- Hypertrophic obstructive cardiomyopathy, active myocarditis, or constrictive pericarditis, or clinically significant congenital heart disease.
- •- Chronic antiarrhythmic therapy, with the exception of amiodarone. Note: For the purposes of this exclusion criterion, digoxin and beta-blocker therapy are not considered to be chronic anti-arrhythmic therapies.
- •- Routinely scheduled outpatient IV infusions for HF (eg, inotropes, vasodilators [eg, nesiritide], diuretics) or routinely scheduled ultrafiltration.
- •- Evidence of digitalis intoxication.
- •Other medical conditions
- •- Blood pressure (BP) > 160/100 mm Hg, systolic BP (SBP) < 90 mm Hg, or heart rate (HR) > 110 bpm or HR < 60 bpm at screening and confirmed by a repeat assessment.
- •- Estimated glomerular filtration rate (eGFR) calculated by the Modification of Diet in Renal Disease (MDRD) equation < 20 mL/min/1.73m2 at screening.
- •- Severe, concomitant non-cardiovascular disease that is expected to reduce life expectancy to less than 1 year.
- •- Recipient of any major organ transplant (eg, lung, liver, heart, bone marrow, renal) or receiving renal replacement therapy by dialysis.
- •- Receiving or has received chemotherapy and/or radiation therapy for treatment of a malignancy within 6 months prior to randomization or clinical evidence of current malignancy, with the following exceptions: localized basal or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia.
- •- Untreated hypothyroidism or hyperthyroidism, adrenal insufficiency, active vasculitis due to collagen vascular disease.
- •- Hepatic impairment defined by a total bilirubin = 2 times the upper limit of normal (ULN), or alanine aminotranferease (ALT) or aspartate aminotransferase (AST) = 5 times ULN at screening.
- •General or other
- •- Previously received omecamtiv mecarbil.
- •- Currently enrolled in another investigational heart failure device or drug study, or less than 30 days since ending another investigational heart failure device or drug study, or receiving other investigational agent(s) for heart failure.
- •Recent (within 3 months) history of alcohol or illicit drug abuse based on self-report.
- •- Known sensitivity to any of the products to be administered during dosing.
- •- Subject previously has entered this study.
- •- Subject will not be available for protocol-required study visits, to the best of the subject’s or investigator’s knowledge.
- •- Any kind of disorder that, in the opinion of t
研究者
相似试验
已完成
3 期
Study assessing impact of additional reduction of bad cholesterol on heart related diseases with AMG 145 when used in combination with cholesterol lowering medicationsCTRI/2014/01/004324Amgen Technology Pvt Ltd266
进行中（未招募）
不适用
A research study to find out if people with Primary Generalized Tonic-Clonic Seizures, by taking perampanel in addition to their normal epilepsy medicine(s), have fewer seizures and feel better. Either perampanel (real medicine) or placebo (pretend medicine that looks the same as the real medicine) will be given in addition to ordinary epilepsy medicines. Who gets which is decided randomly. There is an option to continue into the Follow-on (Extension) Phase of the study.Primary Generalized Tonic-Clonic SeizuresMedDRA version: 17.0Level: HLTClassification code 10018101Term: Generalised tonic-clonic seizuresSystem Organ Class: 100000004852EUCTR2011-000265-12-PLEisai Limited164
进行中（未招募）
1 期
A Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events when AMG 145 is used in combination With Statin Therapy In Patients with Clinically Evident Cardiovascular DiseaseMedDRA version: 16.1Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861DyslipidemiaEUCTR2012-001398-97-NOAmgen Inc27,564
进行中（未招募）
不适用
A Double-blind, Randomized, Placebo-controlled, Multicenter Study toAssess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality andMorbidity in Heart Failure (HF) Subjects with Symptomatic Left VentricularSystolic Dysfunction and Anemia. - RED-HF Trial – Reduction of Events with Darbepoetin alfa in Heart Failure TrialHeart Failure Subjects with Symptomatic Left Ventricular Systolic Dysfunction and AnemiaMedDRA version: 8.1Level: PTClassification code 10007559Term: Cardiac failure congestiveEUCTR2005-005278-59-ATAmgen Inc.3,400
进行中（未招募）
1 期
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or StrokeDyslipidemiaMedDRA version: 21.0Level: LLTClassification code 10058110Term: DyslipidemiaSystem Organ Class: 100000004861EUCTR2018-004565-14-FIAmgen Inc.12,000